This December, 60+ thought-leaders including neuro-oncologists, neurosurgeons and oncology professionals from biopharma will be converging at the first industry led Glioblastoma Drug Development Summit under a common goal of accelerating the practical discovery, translation and clinical development of safe, effective and deliverable therapies to treat glioblastoma.

This meeting provides a truly unique platform for discussions aimed specifically at helping you not only successfully translate drug candidates into human clinical trials, but optimize the clinical development itself to avoid more clinical failures.

Gain exclusive insights into tackling specific and applied drug development challenges limiting effective therapies. This includes tumor heterogeneity, redundant pathway signalling, the immunosuppressive tumor environment and penetration through the blood-brain barrier.

With an increasing number of failed phase II trials and a very poor standard of care, there has never been a more important time to attend the Glioblastoma Drug Development Summit and join those striving to advance safe and effective therapeutic breakthroughs to patients in need.